

CAN - Cures Acceleration Network-The CAN Act seeks to cut the time between discovery and development of drugs and therapies through new grant-making mechanisms at NIH. It will establish CAN within the Office of the Director of NIH and authorize grants expected to move discoveries from the lab into the next generation of therapies. CAN will be overseen by a Board of 24 diverse members from several fields, including research, FDA, venture capital, and patient advocacy. In addition, CAN will work with the FDA to coordinate approval requirements with the goal of expediting the development and approval of products. The legislation authorizes up to \$500 million for CAN for the upcoming years.

NCATS - National Center for Advancing Translational Sciences- The mission is to advance the discipline of translational science and catalyze the development of novel diagnostics and therapeutics across a wide range of human diseases and conditions.

TRND - Therapeutics for Rare and Neglected Diseases program. The National Institutes of Health (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program is a congressionally mandated effort to encourage and speed the development of new drugs for rare and neglected diseases. The federal budget for fiscal 2009 dedicated \$24 million to establish this initiative. TRND will bridge the wide gap in time and resources that often exists between basic research and human testing of new drugs. The effort is grounded in, but aims to improve upon, existing processes for drug development in the pharmaceutical industry.

The Pipeline- the process a drug travels through from discovery to approval by the FDA for therapy for patients.

Re-engineering the pipeline- Making the process faster and smoother from discovery of the drug to approval by the FDA for patients.